Published in J Clin Microbiol on March 19, 2014
Cryptococcosis diagnosis and treatment: What do we know now. Fungal Genet Biol (2014) 1.02
Detection of High Cerebrospinal Fluid Levels of (1→3)-β-d-Glucan in Cryptococcal Meningitis. Open Forum Infect Dis (2014) 0.86
Rising to the challenge of multiple Cryptococcus species and the diseases they cause. Fungal Genet Biol (2015) 0.85
Genotypic Diversity Is Associated with Clinical Outcome and Phenotype in Cryptococcal Meningitis across Southern Africa. PLoS Negl Trop Dis (2015) 0.80
Genomic epidemiology of Cryptococcus yeasts identifies adaptation to environmental niches underpinning infection across an African HIV/AIDS cohort. Mol Ecol (2016) 0.79
Comparative analyses of clinical and environmental populations of Cryptococcus neoformans in Botswana. Mol Ecol (2015) 0.79
Microevolution of Serial Clinical Isolates of Cryptococcus neoformans var. grubii and C. gattii. MBio (2017) 0.75
Glucosamine stimulates pheromone-independent dimorphic transition in Cryptococcus neoformans by promoting Crz1 nuclear translocation. PLoS Genet (2017) 0.75
Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS (2009) 16.37
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis (2010) 11.65
Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol (1982) 6.78
Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS (2005) 5.08
Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med (2010) 2.94
Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol (2009) 2.80
The biology of the Cryptococcus neoformans species complex. Annu Rev Microbiol (2006) 2.31
Multilocus sequence typing reveals three genetic subpopulations of Cryptococcus neoformans var. grubii (serotype A), including a unique population in Botswana. Genetics (2005) 2.16
Poor long-term outcomes for cryptococcal meningitis in rural South Africa. S Afr Med J (2011) 1.83
Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China. Emerg Infect Dis (2008) 1.72
Evidence of sexual recombination among Cryptococcus neoformans serotype A isolates in sub-Saharan Africa. Eukaryot Cell (2003) 1.71
Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol (2005) 1.61
Comparative analysis of environmental and clinical populations of Cryptococcus neoformans. J Clin Microbiol (2005) 1.48
Diploids in the Cryptococcus neoformans serotype A population homozygous for the alpha mating type originate via unisexual mating. PLoS Pathog (2009) 1.35
Prevalence of the VNIc genotype of Cryptococcus neoformans in non-HIV-associated cryptococcosis in the Republic of Korea. FEMS Yeast Res (2010) 1.32
Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence. Antimicrob Agents Chemother (2009) 1.31
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother (2012) 1.28
Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: the role of inadequate secondary prophylaxis. S Afr Med J (2010) 1.16
Low diversity Cryptococcus neoformans variety grubii multilocus sequence types from Thailand are consistent with an ancestral African origin. PLoS Pathog (2011) 1.13
Evidence that the human pathogenic fungus Cryptococcus neoformans var. grubii may have evolved in Africa. PLoS One (2011) 1.07
Population genetic analyses reveal the African origin and strain variation of Cryptococcus neoformans var. grubii. PLoS Pathog (2012) 1.03
Managing cryptococcosis in the immunocompromised host. Curr Opin Infect Dis (2008) 1.02
Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002-2003 and 2007-2008. Antimicrob Agents Chemother (2011) 0.96
Analyses of pediatric isolates of Cryptococcus neoformans from South Africa. J Clin Microbiol (2010) 0.96
Azole heteroresistance in Cryptococcus neoformans: emergence of resistant clones with chromosomal disomy in the mouse brain during fluconazole treatment. Antimicrob Agents Chemother (2013) 0.95
Dynamic and heterogeneous mutations to fluconazole resistance in Cryptococcus neoformans. Antimicrob Agents Chemother (2001) 0.91
Management of cryptococcosis: how are we doing? PLoS Med (2007) 0.84
Long-term follow-up and survival of antiretroviral-naive patients with cryptococcal meningitis in the pre-antiretroviral therapy era, Gauteng Province, South Africa. Int J STD AIDS (2011) 0.84
Determination of epidemiology of clinically isolated Cryptococcus neoformans strains in Japan by multilocus sequence typing. Jpn J Infect Dis (2013) 0.82
Streptococcus pneumoniae Serotypes and Mortality in Adults and Adolescents in South Africa: Analysis of National Surveillance Data, 2003 - 2008. PLoS One (2015) 0.83
HIV Infection and the Epidemiology of Invasive Pneumococcal Disease (IPD) in South African Adults and Older Children Prior to the Introduction of a Pneumococcal Conjugate Vaccine (PCV). PLoS One (2016) 0.78
Prevalence and Hospital Management of Amphotericin B Deoxycholate-Related Toxicities during Treatment of HIV-Associated Cryptococcal Meningitis in South Africa. PLoS Negl Trop Dis (2016) 0.77
Invasive Neisseria meningitidis with decreased susceptibility to fluoroquinolones in South Africa, 2009. J Antimicrob Chemother (2010) 0.77
Typhoid Fever in South Africa in an Endemic HIV Setting. PLoS One (2016) 0.75